Tel: 1-631-626-9181 (USA)   44-207-097-1828 (Europe)


Our promise to you:
Guaranteed product quality, expert customer support.



Fig. 1 Potential therapeutic uses of CpG ODNs. [1]

CpG oligodeoxynucleotides (or CpG ODN) are short single-stranded synthetic DNA molecules containing unmethylated CpG motifs derived from bacterial DNA. CpG ODNs can directly stimulate B-lymphocytes, dendritic and NK cells, resulting in an increase in innate immunity and antibody-dependant cell cytotoxicity (ADCC). Forthermore, it also can indirectly modulate T-cell responses, through the release of cytokines (IL-12 and IFN gamma), to induce a preferential shift to the Th1 (helper) phenotype resulting in enhanced CD8+ cellular cytotoxicity. Preclinical and clinical trials indicate that CpG ODNs can boost the immunogenicity of vaccines targeting infectious diseases and cancer, including acting as vaccine adjuvants to improve antigen-presenting cell function and promoting the induction of an antigen-specific adaptive immune response, preventing allergy by encouraging the development of T helper 1 (TH1)-type immune responses and so on. The characteristics of CpG ODN makes it is possible to better service to the research of vaccine and the immunotherapy of cancer.

As a leading biotechnology company in the world, Creative Biogene possesses sophisticated equipments, advanced technologies and highly experienced staffs which are available to provide you with serious of high-quality CpG ODN products, including type A ODNs, type B ODNs and type C ODNs. Creative Biogene’s goal is to provide you with the most affordable and high-quality CpG ODN products to ensure your satisfaction in a timely and professional manner.


  1. Klinman DM. (2004). Immunotherapeutic uses of CpG oligodeoxynucleotides. Nature Reviews Immunology, 4(4), 249.
  2. Bode C, et al. (2011). CpG DNA as a vaccine adjuvant. Expert review of vaccines, 10(4), 499-511.